Sagimet Biosciences Inc. Series A financials
$9.44−5.03%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $2.0M |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $2.0M |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | 100.0% |
| Operating income | -$15.8M | -$11.7M | -$10.8M | -$14.3M | -$11.9M | -$19.9M | -$18.2M | -$16.9M | -$10.6M | -$8.8M | -$9.5M | -$7.5M |
| Net income | -$14.0M | -$10.7M | -$9.6M | -$12.9M | -$10.4M | -$18.2M | -$16.2M | -$14.6M | -$8.1M | -$6.6M | -$8.2M | -$6.4M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | −317.6% |
| Diluted EPS | $-0.26 | $-0.33 | $-0.29 | $-0.40 | $-0.32 | $-0.56 | $-0.50 | $-0.45 | $-0.25 | $-0.23 | $-0.35 | $-0.35 |
| EBITDA | -$15.8M | -$11.7M | -$10.8M | -$14.3M | -$11.9M | -$19.9M | -$18.2M | -$16.9M | -$10.6M | -$8.8M | -$9.5M | -$7.5M |
| Operating cash flow | -$11.1M | -$8.6M | -$11.8M | -$10.2M | -$9.1M | -$14.5M | -$11.0M | -$19.6M | -$5.6M | -$6.2M | -$7.1M | -$3.9M |
| Free cash flow | -$11.1M | -$8.6M | -$11.8M | -$10.2M | -$9.1M | -$14.5M | -$11.0M | -$19.6M | -$5.6M | -$6.2M | -$7.1M | -$3.9M |
| Diluted shares | 53.1M | 32.6M | 32.5M | 32.5M | 32.2M | 32.2M | 32.3M | 32.1M | 31.9M | 29.0M | 23.3M | 18.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $165.9M | $36.6M | $35.0M | $32.5M | $42.3M | $64.7M |
| Short-term investments | $74.2M | $67.9M | $78.1M | $84.2M | $83.1M | $79.9M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $263.4M | $107.8M | $116.5M | $128.4M | $137.4M | $146.2M |
| Total liabilities | $7.3M | $5.3M | $5.1M | $9.1M | $7.2M | $7.2M |
| Shareholders' equity | $256.2M | $102.5M | $111.4M | $119.3M | $130.2M | $139.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology